MORARI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.950
NA - Nord America 2.427
EU - Europa 1.397
AF - Africa 887
SA - Sud America 786
OC - Oceania 94
Continente sconosciuto - Info sul continente non disponibili 42
Totale 8.583
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.954
SG - Singapore 1.170
BR - Brasile 475
CN - Cina 375
HK - Hong Kong 314
VN - Vietnam 206
IT - Italia 177
PL - Polonia 94
RU - Federazione Russa 87
FR - Francia 85
NL - Olanda 84
DE - Germania 71
AR - Argentina 70
KR - Corea 60
FI - Finlandia 52
IQ - Iraq 45
EC - Ecuador 43
ZA - Sudafrica 43
CI - Costa d'Avorio 41
GB - Regno Unito 40
ES - Italia 39
TR - Turchia 39
MX - Messico 38
ID - Indonesia 37
AT - Austria 35
IN - India 35
DO - Repubblica Dominicana 34
IL - Israele 34
PE - Perù 32
GH - Ghana 31
JO - Giordania 31
RS - Serbia 31
EG - Egitto 30
GT - Guatemala 30
MR - Mauritania 30
UA - Ucraina 30
CO - Colombia 29
VE - Venezuela 29
IE - Irlanda 28
LB - Libano 28
LV - Lettonia 28
PA - Panama 28
SA - Arabia Saudita 28
SN - Senegal 28
CG - Congo 27
CY - Cipro 27
IR - Iran 27
SE - Svezia 27
SO - Somalia 27
UZ - Uzbekistan 27
YT - Mayotte 27
AL - Albania 26
AZ - Azerbaigian 26
BZ - Belize 26
GF - Guiana Francese 26
GR - Grecia 26
HN - Honduras 26
KE - Kenya 26
ME - Montenegro 26
NP - Nepal 26
PR - Porto Rico 26
BY - Bielorussia 25
CR - Costa Rica 25
CZ - Repubblica Ceca 25
NI - Nicaragua 25
PK - Pakistan 25
JP - Giappone 24
KZ - Kazakistan 24
LC - Santa Lucia 24
UY - Uruguay 24
BA - Bosnia-Erzegovina 23
BB - Barbados 23
BE - Belgio 23
BJ - Benin 23
CA - Canada 23
GE - Georgia 23
MA - Marocco 23
MK - Macedonia 23
MN - Mongolia 23
NE - Niger 23
AM - Armenia 22
AO - Angola 22
BW - Botswana 22
CW - ???statistics.table.value.countryCode.CW??? 22
KG - Kirghizistan 22
KH - Cambogia 22
LA - Repubblica Popolare Democratica del Laos 22
UG - Uganda 22
ZM - Zambia 22
AD - Andorra 21
CH - Svizzera 21
CL - Cile 21
ET - Etiopia 21
GM - Gambi 21
GN - Guinea 21
IS - Islanda 21
LY - Libia 21
MD - Moldavia 21
MZ - Mozambico 21
RO - Romania 21
Totale 7.577
Salva come PNG Salva come JPEG
Città #
Singapore 676
Ashburn 308
Hong Kong 300
Santa Clara 180
Boardman 133
Hefei 121
Fairfield 114
Beijing 98
Woodbridge 83
Los Angeles 72
Ho Chi Minh City 70
Bytom 61
Chandler 61
Houston 57
Redondo Beach 52
Hanoi 48
Buffalo 46
Seoul 44
Seattle 42
Abidjan 40
Wilmington 39
Padova 38
New York 36
Chicago 35
São Paulo 35
Cambridge 33
Amman 30
Nouakchott 28
Dakar 27
Accra 26
Panama City 26
Managua 24
Baku 23
Montevideo 23
Riga 23
Tashkent 23
Vienna 23
Athens 22
Bridgetown 22
Castries 22
Cotonou 22
Dublin 22
Helsinki 22
Kampala 22
Phnom Penh 22
Bishkek 21
Conakry 21
Kigali 21
Lusaka 21
Nairobi 21
Niamey 21
Andorra la Vella 20
Minsk 20
Ulan Bator 20
Ann Arbor 19
Johannesburg 19
Kingstown 19
Luanda 19
Noumea 19
Addis Ababa 18
Frankfurt am Main 18
Maputo 18
Nassau 18
Ogden 18
Podgorica 18
Quito 18
Reykjavik 18
Tokyo 18
Cayenne 17
Dili 17
Gaborone 17
Guayaquil 17
Harare 17
Lima 17
Mamoudzou 17
Vientiane 17
Warsaw 17
Amsterdam 16
Antananarivo 16
Dong Ket 16
Havana 16
Milan 16
San José 16
Tbilisi 16
Bamako 15
Brazzaville 15
Dar es Salaam 15
Guatemala City 15
Libreville 15
Papeete 15
Praia 15
San Diego 15
Santo Domingo 15
Tirana 15
Boston 14
Curitiba 14
Dallas 14
Port Moresby 14
Salt Lake City 14
Skopje 14
Totale 4.216
Salva come PNG Salva come JPEG
Nome #
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 225
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 207
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain 190
Role of LRRK2 in the regulation of dopamine receptor trafficking 182
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 165
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation 152
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex 151
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata 131
Dopamine neuron dysfunction and loss in the PrknR275W mouse model of juvenile parkinsonism 124
Early dysfunction of substantia nigra dopamine neurons in the parkinq311x mouse 113
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease 110
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology 106
Modeling Parkinson's disease in LRRK2 mice: Focus on synaptic dysfunction and the autophagylysosomal pathway 101
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models 100
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter 96
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates 95
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo 94
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity 93
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 89
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance 89
Autophagy and LRRK2 in the Aging Brain 87
Development of a new toolbox for mouse PET-CT brain image analysis fully based on CT images and validation in a PD mouse model 85
Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice 82
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity 78
Viral mediated α-synuclein overexpression results in greater transgene levels and α-synuclein overload in mice bearing kinase dead mutation of LRRK2 78
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 78
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 76
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia 76
Nociceptin/orphanin FQ receptor agonists as a novel therapy for preventing levodopa-induced dyskinesia 75
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 74
Modeling Parkinson’s disease in LRRK2 rodents 74
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 74
NOP receptor ligands and Parkinson’s disease 73
Managing Parkinson's disease: moving ON with NOP 72
Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice 72
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study 70
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 69
Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats. New insights into the role of delta receptors in parkinsonism 68
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices 67
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 66
5-Hydroxytryptamine-mediated effects of nicotine on endogenous GABA efflux from guinea-pig cortical slices 65
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 64
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 64
Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation 64
Nociceptin/orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata 64
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 64
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease 64
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 64
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 63
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 63
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 63
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 63
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 62
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs 62
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 62
NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms 62
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 61
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 61
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 61
Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia 61
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat-II. Evidence for a N-methyl-D-aspartate receptor regulation of striatonigral GABAergic transmission and motor function 61
Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-Cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4) 61
Parkinson's disease: no NOP, new hope 61
The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway 60
PRIN 2010-2011. Ente finanziatore MIUR. titolo "Discinesie indotte da L-DOPA nella malattia di Parkinson: nuovi meccanismi e target molecolari" 59
Neuronal vulnerability following inhibition of mitochondrial complex II: a possibile ionic mechanism for Huntington’s disease 59
NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways 57
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance 57
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity 57
An innovative approach to treat levodopa-induced dyskinesia based on targeting striatal intracellular signalling. Ente finanziatore Fondazione S. Paolo 57
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 56
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats 56
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia 56
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 56
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats 55
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat 55
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 55
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 54
Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism 54
Enhancement of D1 dopaminergic responses in aged LRRK2 G2019S knock-in mice 54
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease 54
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 53
Reciprocal dopamine-glutamate modulation of release in the basal ganglia 53
PRIN 2008. ente finanziatore MIUR. titolo"Nuovi approcci terapeutici per le discinesie indotte dal trattamento con L-DOPA in un modello sperimentale di Parkinson: ruolo delle subunità del recettore NMDA e della via molecolare Ras-ERK" 53
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 53
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 53
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 52
Synthesis and structure activity relationships of delthorphine analogues 52
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 51
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 51
Progetto Telethon 2012. (Ente finanziatore Fondazione Telethon) Funzione e disfunzione a livello presinaptico di LRRK2, una proteina chinasi associata alla malattia di Parkinson 51
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 50
In vitro evidence for increased facilitation of striatal acetylcholine release via pre- and postsynaptic NMDA receptors in hemiparkinsonian rats 49
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 49
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism 49
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 49
Mitochondrial targeting in LRRK2-associated parkinsonism (PARK8) 49
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 48
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 48
Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid 47
Totale 7.518
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.569
article - articoli 23.540
book - libri 147
conference - conferenze 0
curatela - curatele 0
other - altro 1.071
patent - brevetti 0
selected - selezionate 0
volume - volumi 682
Totale 52.009
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202181 0 0 0 0 9 3 0 6 14 17 13 19
2021/2022137 10 8 19 10 4 9 5 23 2 6 7 34
2022/202399 22 13 1 19 13 9 0 5 12 1 1 3
2023/2024447 1 6 6 26 14 10 20 134 61 9 65 95
2024/20252.254 10 184 99 74 345 70 77 119 211 100 380 585
2025/20265.409 392 584 1.802 1.901 730 0 0 0 0 0 0 0
Totale 8.744